Related Experiment Video
Updated: Jul 13, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
[Efficacy and tolerance of non nucleosidic reverse transcriptase inhibitors containing tritherapy in HIV-1 infection]
C T Ndour1, N F Ngom Gueye, M Soumare
1Clinique des maladies infectieuses Ibrahima Diop Mar, CHU de Fann, Université Cheikh Anta Diop, BP 5035, Dakar, Sénégal. elhaji3@yahoo.com
Introduction:
Antiretroviral therapy has dramatically changed the natural history of HIV infection. The aim of this study was to evaluate the effectiveness and tolerance of Non Nucleosidic Reverse Trancriptase Inhibitors containing regimens in HIV-1 infection.
Patients And Methods:
This is a retrospective chart review of 257 HIV-1 infected patients followed in the infectious clinic ward of fann, from august 1998 to February 2002.
Results:
Overall 195 patients (75.87%) were on efavirenz and 62 (25.2%) on nevirapine, with a male predominance (sex-ratio = 1.44). Baseline HIV-1 viral load was higher in efavirene group (p = 0.03). The two groups were comparable for immune restoration, tolerance, rate of treatment discontinuation and letality. The viral suppression was greater in efavirenz group at month 6 (p = 0.04).
Conclusion:
Non nucleosidic reverse transcriptase inhibitor containing regimens are effective and well tolerated. Those results make them suitable for first line therapy in HIV-1-infection.
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Inhibitors of Virion Maturation and Assembly
Therapeutic Drug Monitoring: Affecting Factors
Trichomoniasis

